Strategies for Managing Special Situations in the Patient with Type 2 Diabetes

Please read the following information and select the appropriate link at the bottom of the page to continue.

Target Audience:
This activity is intended for physicians, pharmacists, nurses, and dietitians who care for patients with type 2 diabetes.

Goal:
The goal of this program is to provide theoretical and practical knowledge to healthcare providers regarding the design of insulin regimens for patients with type 2 diabetes who have special situations.

Educational Objectives:
Upon completion of this activity, the participant should be able to:

• Identify frequently occurring and uncommon special situations that necessitate individually tailored insulin regimens for persons with type 2 diabetes.
• Provide patient education regarding the benefits of frequent self-monitoring of blood glucose for persons with special situations.
• Select the appropriate insulin and insulin delivery methods for persons with special situations.
• Identify key resources that provide guidance for developing insulin regimens for persons with special situations.

Accreditation:
In order to receive your CME Certificate or Statement of Credit, you must complete the activity, the post test, and evaluation. Your statement of credit will be issued immediately upon completion of the test and submission of the evaluation form.

Release Date: December 15, 2007
Expiration Date: December 15, 2009

	Physician Credit: The American Academy of CME, Inc. designates this educational activity for a maximum of 2.00 AMA PRA Category 1 Credit(s)™. Physicians should only claim credit commensurate with the extent of their participation in the activity.
	Pharmacists: The American Academy of CME, Inc. is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. This program provides 2.00 contact hours (0.200 CEUs) of continuing education credit. ACPE Universal Program Number 297-999-07-028-H01-P.
	Registered Nurses: The American Academy of CME, Inc. (Academy) is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center's Commission on Accreditation. The Academy designates this educational activity for 2.00 contact hours. ANCC Accredited Providers have been approved by The National Certification Board for Diabetes Educators (NCBDE) as providers of continuing education. Individuals seeking recertification from the NCBDE can use continuing education contact hours received through participation in this activity.
	Dietitians: The American Academy of CME, Inc. is a Continuing Professional Education (CPE) Accredited Provider with the Commission on Dietetic Registration (CDR) from June 1, 2006 to May 31, 2009. Registered dietitians (RD) and dietetic technicians, registered (DTR) will receive 2.00 Continuing Professional Education Units (CPEUs) for completion of this program. Continuing Professional Education Provider Accreditation does not constitute endorsement by CDR of a provider, program, or materials.

Your statement of credit will be issued immediately upon completion of the test and submission of the evaluation form. The statement of credit will appear on your screen and you will be given the option to print it for your files. No additional statement of credit will be issued.

Editorial Review Board:

Barbara Kocurek, PharmD, BCPS, CDE
Diabetes Education Coordinator
Baylor Health Care System
Dallas, Texas

Virginia Peragallo-Dittko, APRN, BC-ADM, MA, CDE
Director, Diabetes Education Center
Winthrop-University Hospital
Mineola, New York

Anne Peters, MD, CDE
Professor of Clinical Medicine
University of Southern California
Los Angeles, California

Gretchen A. Youssef, MS, RD, CDE
Program Manager
MedStar Diabetes Institute
Washington, DC

Editorial Review Board Disclosures:
According to the disclosure policy of the Academy, faculty, planning committee members, editors, managers, and other individuals who are in a position to control content are required to disclose any relevant relationships with commercial companies related to this activity. If a conflict is identified, it is the responsibility of the Academy to initiate a mechanism to resolve the conflict(s). The existence of these interests or relationships is not viewed as implying bias or decreasing the value of the presentation. All educational materials are reviewed for fair balance, scientific objectivity of studies reported, and levels of evidence.

Barbara Kocurek, PharmD, BCPS, CDE, has no relevant financial disclosures.

Virginia Peragallo-Dittko, APRN, BC-ADM, MA, CDE, has disclosed that she has been a member of the scientific advisory board of Novo Nordisk, Inc.

Anne Peters, MD, CDE, has disclosed that she has been a member of the Takeda, Eli Lilly and Company, and Amylin advisory boards for scientific information. She has received grants/research support from Abbott Laboratories. She is member of the promotional speakers bureaus of Abbott Laboratories, Amylin, Aventis, Eli Lilly and Company, and Takeda.

Gretchen A. Youssef, MS, RD, CDE, has disclosed that she is a member of the advisory boards for scientific information of Amylin and Eli Lilly and Company. She is a member of the marketing advisory board of Novo Nordisk, Inc. She has been a grant recipient or received research support from Abbott Laboratories.

Planning Committee Disclosures:
Edward J. Moylan, RP, of the American Academy of CME, Inc, has no relevant financial disclosures.

Peter Macholdt of Scherer Clinical Communications has no relevant financial disclosures.

Natalie Kirkwood, JD, RN, has no relevant financial disclosures.

The following individuals provided dietetic review and none of them have any relevant financial disclosures: Kristin Gusack, RD; Angela Sims, RD, LD; Amanda LaVoie, MS, RD; and Kerry Rose, RD.

Disclaimers:

• Approval of credit for this continuing education (CE) program does not imply endorsement by the American Academy of CME, Inc. or Scherer Clinical Communications of any product or manufacturer identified.
• Any medications or treatment methods suggested in this CE activity should not be used by the practitioner without evaluation of their patient’s condition(s) and possible contraindication(s) or danger(s) of use of any specific medication.
• This activity may include discussions of products or devices that are not currently approved for use by the US Food and Drug Administration (FDA).
• The American Academy of CME, Inc, Scherer Clinical Communications, the Editorial Review Board, and the commercial supporter do not endorse the use of any product in a manner that is not approved by the FDA.

The Editorial Review Board, sponsor, and publisher of this continuing education program have made all reasonable efforts to ensure that information contained herein is accurate in accordance with the latest available scientific knowledge at the time of accreditation of this continuing education program. Information regarding drugs (eg, administration, dosages, contraindications, adverse reactions, interactions, special warnings, precautions) and drug delivery systems is subject to change, however, and the reader is advised to check the manufacturer’s package insert for information concerning recommended dosage and potential problems or cautions prior to dispensing or administering the drug or using the drug delivery systems.

Trademarks:

• Lantus is a registered trademark of Aventis Pharmaceuticals Inc.
• Humulin, Humalog, and Humalog Mix75/25 are registered trademarks of Eli Lilly and Company.
• Levemir, Novolin, NovoLog, and NovoLog Mix 70/30 are registered trademarks of Novo Nordisk A/S.

Fee:
There is no fee to receive credits for this continuing education activity.

Commercial Supporter:
This program is supported by an educational grant from Novo Nordisk Inc.

Software Requirements:

Click the appropriate profession to continue to the activity:

Copyright^© 2007 Scherer Clinical Communications. All rights reserved.